• There are no published controlled studies of FeL therapy.
  • In the absence of evidence indicating otherwise, empirical treatment giving the same drugs recommended for dogs is usually considered effective and apparently safe. Allopurinol (10 mg/kg 12 h or 20 mg/kg 24 h P.O., for at least 6 months) has been more frequently used than meglumine antimoniate (20-50 mg/kg 24 h S.C., for 30 days). These two drugs have also been given in combination.
  • Cats under therapy with allopurinol or meglumine antimoniate should be carefully monitored for any adverse effects.

Disclaimer: Information given here on drugs and dosages are based on a consensus of clinical and scientific experience by the LeishVet members. These recommendations have been published in scientific peer-reviewed scientific journals. Veterinary practitioners are requested to check with product leaflets and product registrations in their related country prior to any product selection and initiation of treatment.

  • Recurrence of clinical signs may occur; careful monitoring after the end of anti-Leishmania treatment should include physical examination, CBC, biochemical profile, urinalysis and quantitative serology at the frequencies indicated below.
  • The life expectancy of cats with FeL is usually good (years) unless concurrent conditions (neoplasia, FIV/FeLV infections) or complications (renal disease) occur.

Follow-up regimen

Physical examination
Biochemical profile
Urinalysis including UPC**
At least weekly (meglumine antimoniate) or fortnightly (allopurinol) during the first month of therapy
Every 3 months in the first year or after stopping therapy
Every 6 months after the first year
Quantitative serology Every 3 months in the first year or after stopping therapy
Every 6 months after the first year

* CBC: complete blood count.
** UPC: urinary protein: creatinine ratio.